Cognition Therapeutics
Clinical trials sponsored by Cognition Therapeutics, explained in plain language.
-
New drug access program offers hope for lewy body dementia patients
Disease control NO_LONGER_AVAILABLEThis program gives people with mild-to-moderate dementia with Lewy bodies access to an experimental drug called CT1812 (Zervimesine) for up to one year. It aims to monitor long-term safety and how well the drug works. Participants must have completed a related study or be referre…
Sponsor: Cognition Therapeutics • Aim: Disease control
Last updated May 26, 2026 11:33 UTC
-
Could a new pill slow Alzheimer's? major trial underway
Disease control OngoingThis study tests an experimental drug called CT1812 in people with early Alzheimer's disease. About 540 participants will receive either the drug or a placebo for 18 months to see if it can slow down memory and thinking problems. The goal is to find a safe treatment that helps co…
Phase: PHASE2 • Sponsor: Cognition Therapeutics • Aim: Disease control
Last updated May 22, 2026 13:54 UTC